VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

ADA 2020

VALBIOTIS selected at the 80th Scientific Sessions of the American Diabetes Association to present Phase II clinical results of TOTUM-63 in prediabetes.

Lire le communiqué de presse

Pipeline

VALBIOTIS accelerates the clinical development of its pipeline in new indications: reducing cardiovascular risk and hepatic steatosis.

Learn more

TOTUM-63

Initiation of the pivotal late stage development phase of TOTUM-63, with Nestlé Health Science

Learn more

VALBIOTIS

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63

Learn more
S c r o l l

Products

.01

TOTUM-63

Prediabetes, risk condition for Type 2 Diabetes
> Clinical Phase II positive
> Clinical Phase II/III pending

Learn more

.02

TOTUM-070

Mild to moderate hypercholesterolemia, risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

.03

TOTUM-448

Non-alcoholic hepatic steatosis, risk condition for NASH
> Clinical Phase II pending

Learn more

.04

TOTUM-854

Elevated blood pressure, a risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

12.06.2020

80th scientific sessions of the American Diabetes Association

En savoir plus
11.02.2020

Investor meetings – Portzamparc

En savoir plus
28.01.2020

Biomed Event

En savoir plus
16.10.2019

French Society of Financial Analysts (SFAF)

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Learn more

Follow us!

See more